ZENTALIS PHARMACEUTICALS INC (ZNTL)
US98943L1070 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 28.04M | 43.10M | 59.70M | 55.00M | 67.20M | |||
| Marketable Securities | 454.88M | 394.30M | 280.20M | 283.60M | N/A | |||
| Receivables | 3.34M | 6.40M | 0.00 | 400.00K | 100.00K | |||
| Other Current Assets | 10.46M | 8.20M | 10.80M | 6.20M | 1.50M | |||
| Total Current Assets | 496.72M | 451.90M | 350.80M | 345.10M | 68.90M | |||
| Non-Current Assets | ||||||||
| PPE Net | 41.73M | 50.10M | 52.80M | 3.60M | 2.80M | |||
| Investments And Advances | 0.00 | 21.20M | 37.50M | N/A | N/A | |||
| Goodwill | 3.74M | 3.70M | 3.70M | 3.70M | 3.70M | |||
| Intangibles | N/A | N/A | 0.00 | 8.80M | 8.80M | |||
| Other Non-Current Assets | 9.50M | 12.40M | 9.70M | 4.30M | 3.20M | |||
| Total Non-Current Assets | 54.97M | 87.40M | 103.70M | 20.50M | 18.60M | |||
| TOTAL ASSETS | 551.69M | 539.30M | 454.50M | 365.60M | 87.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 54.16M | 45.00M | 31.40M | 19.50M | 10.60M | |||
| Accounts Payable | 14.93M | 11.20M | 11.60M | 8.70M | 4.30M | |||
| Other Current Liabilities | 281.00K | 400.00K | 1.00M | 400.00K | 0.00 | |||
| Total Current Liabilities | 69.37M | 56.60M | 43.90M | 28.60M | 14.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | 0.00 | 900.00K | 1.60M | 2.50M | 2.50M | |||
| Other Non-Current Liabilities | 44.93M | 47.80M | 44.50M | 1.10M | 1.70M | |||
| Total Non-Current Liabilities | 45.04M | 48.90M | 46.70M | 28.40M | 11.00M | |||
| TOTAL LIABILITIES | 114.40M | 105.50M | 90.60M | 57.00M | 25.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -888.56M | -596.40M | -359.60M | -200.80M | -83.00M | |||
| Additional Paid In Capital | 1.32B | 1.03B | 723.60M | 509.30M | N/A | |||
| Minority Interest | 221.00K | 510.00K | 7.87M | 25.51M | 7.52M | |||
| Common Shares | 70.00K | 100.00K | 0.00 | 0.00 | 144.60M | |||
| Other Shareholders' Equity | 2.19M | N/A | N/A | N/A | N/A | |||
| Shares Outstanding | 70.77M | 59.30M | 45.50M | 41.00M | 34.50M | |||
| Tangible Book Value per Share | 6.13 | 7.25 | 7.92 | 7.22 | -2.68 | |||
| Total Shareholders' Equity | 437.28M | 433.80M | 364.00M | 308.60M | 61.60M | |||
| TOTAL LIABILITIES AND EQUITY | 551.69M | 539.30M | 454.50M | 365.60M | 87.50M | |||
| Statistics | ||||||||
| Current Ratio | 7.16 | 7.98 | 7.99 | 12.07 | 4.62 | |||
| Return On Assets (ROA) | -52.96% | -43.91% | -34.92% | -32.23% | -52.18% | |||
| Return On Equity (ROE) | -66.82% | -54.59% | -43.61% | -38.19% | -74.12% | |||
All data in USD